The concentration of oxazepam and oxazepam glucuronide in oral fluid, blood and serum after controlled administration of 15 and 30 mg oxazepam

被引:30
作者
Smink, Beitske E. [1 ]
Hofman, Berendina J. A. [1 ,5 ]
Dijkhuizen, Albert [1 ]
Lusthof, Klaas J. [1 ]
de Gier, Johan J. [2 ]
Egberts, Antoine C. G. [3 ,4 ]
Uges, Donald R. A. [5 ]
机构
[1] Netherlands Forens Inst, Dept Toxicol, NL-2497 GB The Hague, Netherlands
[2] Univ Groningen, Dept Pharmacotherapy & Pharmaceut Care, Groningen, Netherlands
[3] Utrecht Inst Pharmaceut Sci, Dept Pharmacoepidemiol & Pharmacotherapy, Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Dept Clin Pharm, Utrecht, Netherlands
[5] Univ Med Ctr Groningen, Dept Pharm Toxicol & Forens Med, NL-9713 AV Groningen, Netherlands
关键词
oral fluid; oxazepam; oxazepam glucuronide; pharmacokinetics;
D O I
10.1111/j.1365-2125.2008.03252.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
AIMS To measure and compare the concentration-time profiles of oxazepam and oxazepam glucuronide in blood, serum and oral fluid within the scope of roadside testing. METHODS Biological samples were collected from eight male subjects after ingestion of 15 or 30 mg oxazepam on separate dosing occasions with an interval of 7 days. The concentration-time profiles of oxazepam and oxazepam glucuronide were fitted by using a one-compartment model. RESULTS For oxazepam and oxazepam glucuronide, the mean oral fluid/blood ratios were 0.05 (range 0.04-0.07) and 0.004 (range 0.002-0.006), respectively. The concentration-time profiles in oral fluid paralleled those in blood. CONCLUSION After oral administration of therapeutic doses of oxazepam, concentrations in oral fluid are very much lower than those in blood, and those of oxazepam glucuronide are much lower than those of the parent compound. Nevertheless, assay of oral fluid for oxazepam can be used to detect recent ingestion of the drug in drivers suspected of impaired driving performance.
引用
收藏
页码:556 / 560
页数:5
相关论文
共 10 条
[1]   Choosing the optimal fit function: Comparison of the Akaike information criterion and the F-test [J].
Glatting, Gerhard ;
Kletting, Peter ;
Reske, Sven N. ;
Hohl, Kathrin ;
Ring, Christina .
MEDICAL PHYSICS, 2007, 34 (11) :4285-4292
[2]  
GREENBLATT DJ, 1980, J PHARMACOL EXP THER, V215, P86
[3]   A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions [J].
Kelly, E ;
Darke, S ;
Ross, J .
DRUG AND ALCOHOL REVIEW, 2004, 23 (03) :319-344
[4]  
MOFFAT AC, 2004, CLARKES ANAL DRUGS P, P1375
[5]   Psychoactive substance use and the risk of motor vehicle accidents [J].
Movig, KLL ;
Mathijssen, MPM ;
Nagel, PHA ;
van Egmond, T ;
de Gier, JJ ;
Leufkens, HGM ;
Egberts, ACG .
ACCIDENT ANALYSIS AND PREVENTION, 2004, 36 (04) :631-636
[6]   DISPOSITION OF OXAZEPAM IN RELATION TO AGE, SEX, AND CIGARETTE-SMOKING [J].
OCHS, HR ;
GREENBLATT, DJ ;
OTTEN, H .
KLINISCHE WOCHENSCHRIFT, 1981, 59 (16) :899-903
[7]   MW PHARM, AN INTEGRATED SOFTWARE PACKAGE FOR DRUG-DOSAGE REGIMEN CALCULATION AND THERAPEUTIC DRUG-MONITORING [J].
PROOST, JH ;
MEIJER, DKF .
COMPUTERS IN BIOLOGY AND MEDICINE, 1992, 22 (03) :155-163
[8]   NORMAL DISPOSITION OF OXAZEPAM IN ACUTE VIRAL-HEPATITIS AND CIRRHOSIS [J].
SHULL, HJ ;
WILKINSON, GR ;
JOHNSON, R ;
SCHENKER, S .
ANNALS OF INTERNAL MEDICINE, 1976, 84 (04) :420-425
[9]   FACTORS AND CONDITIONS AFFECTING THE GLUCURONIDATION OF OXAZEPAM [J].
SONNE, J .
PHARMACOLOGY & TOXICOLOGY, 1993, 73 :1-23
[10]   BIOAVAILABILITY AND PHARMACOKINETICS OF OXAZEPAM [J].
SONNE, J ;
LOFT, S ;
DOSSING, M ;
VOLLMERLARSEN, A ;
OLESEN, KL ;
VICTOR, M ;
ANDREASEN, F ;
ANDREASEN, PB .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 35 (04) :385-389